SCHEMBL4248324

SCHEMBL4248324

CN1C(=O)/C(=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)SC1=S

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.71
MAPT P10636 2/20 0.71
ALDH1A1 P00352 1/20 0.71
LMNA P02545 1/20 0.71
RAB9A P51151 1/20 0.71
MAP3K5 Q99683 3/20 0.69
PTPN12 Q05209 1/20 0.65
PTPN22 Q9Y2R2 1/20 0.65
DUSP3 P51452 1/20 0.63
BRAF P15056 1/20 0.55
GSK3A P49840 1/20 0.54
GSK3B P49841 1/20 0.54
STAT3 P40763 1/20 0.51
HIF1AN Q9NWT6 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
PSMB8 P28062 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3906963 1.00 POLB (0.71) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL4248327 1.00 POLB (0.71) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL3892790 0.87 MAPT (0.69) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL7859600 0.87 MAPT (0.69) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL3892793 0.87 MAPT (0.69) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL23692502 0.86 PTPN12 (0.85) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL14859671 0.86 PTPN12 (0.85) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL14859674 0.86 PTPN12 (0.85) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL6398025 0.85 MAP3K5 (0.75) POLBMAPTALDH1A1LMNARAB9A
SCHEMBL6398030 0.85 MAP3K5 (0.75) POLBMAPTALDH1A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 WO claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 US disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 POLB 2008/4885MAPT 1187/4885ALDH1A1 1828/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 POLB 433/4885MAPT 880/4885ALDH1A1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.